Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline treatment in patients with ACTH-dependent Cushing's syndrome
2010-018720-12Phase 2Active
- Sponsor
- Swedish Pituitary Study Group
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabergoline in ACTH-dependent Cushing's syndrome and Corticotropin adenoma (ACTHoma), sponsored by Swedish Pituitary Study Group. Primary endpoint: Urinary free cortisol normalization. Started Feb 2010; status: active.
02
Drugs
cabergoline
03
Conditions
ACTH-dependent Cushing's syndromeCorticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2010-018720-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018720-12.